NCT05372614 2026-03-19
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
National Cancer Institute (NCI)
SynerGene Therapeutics, Inc.
Eisai Inc.
Synta Pharmaceuticals Corp.
Eisai Inc.
Adherex Technologies, Inc.
Exelixis